ALT5 Sigma to spin off healthcare assets into Alyea; LOI to acquire Soin Bioscience pain patch tech

AI Financial Corp

All director nominees re-elected; CEO Peter Tassiopoulos elected to board for first time.
Fintech platforms ALT5 Pay and Prime surpassed $2B in transaction volume in 2024.
Spin-off of healthcare assets into Alyea Therapeutics planned for H1 2025 to unlock value.
Alyea executed non-binding LOI to acquire Soin Bioscience's clear pain patch technology; market $4.8B, expected $7.33B by 2031.
Alyea preparing pivotal trials for LDN for complex regional pain syndrome; FDA Orphan Drug designation granted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.